Sanofi-Aventis and its lawyers at Ropes & Gray are accusing rival drugmaker Novo Nordisk Inc. of launching a false advertising campaign about the availability of Sanofi’s insulin drugs, Lantus and Toujeo.
According to a suit filed Dec. 23 in New Jersey federal court, Novo Nordisk sought to capitalize on a decision in August by prescription benefit manager CVS Caremark that removed Lantus and Toujeo from its standard formulary and replaced them with Basaglar, a product made by Eli Lilly & Co. A month later Novo Nordisk launched a nationwide marketing campaign that Sanofi complains falsely and misleadingly described the effects of CVS’s change, saying the Sanofi drugs would be “blocked” and urging doctors to convert patients to Tresiba.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
